SIM
CYTK icon

Spark Investment Management’s Cytokinetics CYTK Stock Holding History

Spark Investment Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-62,400
Closed -$755K – 728
2017
Q2 		$755K Sell
62,400
-3,300
-5% -$45.9K 0.05% 441
2017
Q1 		$844K Buy
+65,700
New +$768K 0.05% 445
2016
Q2 		– Sell
-100,500
Closed -$708K – 798
2016
Q1 		$708K Sell
100,500
-42,700
-30% -$312K 0.07% 369
2015
Q4 		$1.5M Buy
143,200
+65,100
+83% +$639K 0.19% 164
2015
Q3 		$520K Buy
78,100
+55,800
+250% +$381K 0.07% 370
2015
Q2 		$149K Buy
+22,300
New +$146K 0.02% 569
2013
Q4 		– Sell
-26,000
Closed -$197K – 665
2013
Q3 		$197K Sell
26,000
-31,433
-55% -$337K 0.05% 449
2013
Q2 		$665K Buy
+57,433
New +$452K 0.18% 159

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Spark Investment Management's CYTK Position: Q3 2017 in Review

Spark Investment Management sold out of Cytokinetics (CYTK) in Q3 2017, closing a stake of 62,400 shares — an estimated $755K sold.

Spark Investment Management first reported a position in CYTK in Q2 2013 and held it in 8 quarters. The position peaked at $1.5M in Q4 2015. 132 funds tracked by Wall St. Rank hold CYTK as of Q3 2017.

  • Spark Investment Management reported no remaining Cytokinetics position as of Q3 2017 after selling out during the quarter.
  • Spark Investment Management sold 62,400 Cytokinetics shares in Q3 2017, an estimated $755K.
  • Spark Investment Management first reported a position in Cytokinetics in Q2 2013 and held it in 8 quarters.
  • Spark Investment Management's Cytokinetics position peaked at $1.5M in Q4 2015.
  • 132 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2017.

Based on Spark Investment Management's 13F filing for Q3 2017, filed 13 Nov 2017.